MEDVi semaglutide: November 2026 price and position
As of November 20, 2026, no current compounded semaglutide price is shown for MEDVi: its page could not be read on November 20, 2026. This record shows no figure rather than an outdated one presented as current.
Released · Last reviewed · how we verify
Why no current price is shown
Its compounded prices did not render on November 20, 2026 (the page showed template placeholders). The August 2026 capture stays in the open dataset with its date. For programs that do print a semaglutide price, see the semaglutide price table.
FDA warning letters
FDA’s warning-letter index lists warning letter 721455 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to MEDVi; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Limitations and what to check before you enroll
Compounded semaglutide is not FDA-approved and is not the same product as Wegovy; it is made for an individual patient by a state-licensed pharmacy. Ask MEDVi for the all-in price at the maintenance dose, what is charged today and how often, and which pharmacy fills the prescription. A clinician decides whether any GLP-1 is right for you.
Frequently asked
How much does MEDVi charge for semaglutide?
As of November 20, 2026, no current compounded semaglutide price is shown for MEDVi: its page could not be read on November 20, 2026. This record shows no figure rather than an outdated one presented as current.
Is MEDVi’s semaglutide FDA-approved?
No. Compounded semaglutide from any telehealth program, MEDVi included, is not FDA-approved and is not the same product as Wegovy or Ozempic. It is made for an individual patient by a state-licensed compounding pharmacy. Brand Wegovy is the FDA-approved version.
Where do these MEDVi figures come from?
From MEDVi’s own page (not readable Nov 20, November 20, 2026), converted to an all-in month-to-month figure (medication plus any required recurring fee, before tax). The source link and read date are listed below, and the same figures are in the open dataset.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- MEDVi pricing page (not readable on November 20, 2026)
- FDA warning letter 721455 to MEDVi (dated 2026-02-20, posted 2026-03-03; read November 20, 2026)